Viking Therapeutics (NASDAQ: VKTX) is operating in one of the highest-growth pharma areas around. Viking doesn't sell weight loss drugs yet, but it could be on the way. The biotech is studying ...

Viking expects to report data from the study in the second half of 2025. The Phase 2 VENTURE-Oral Dosing Trial is a randomized, double-blind, placebo-controlled multicenter study designed to ...

interest in participating in the Phase 2 VENTURE-Oral study was high and drove an efficient rate of enrollment," said Brian Lian, Ph.D., chief executive officer of Viking Therapeutics.